Related Experiment Videos
APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers
Amy V Gerstein1, Teresa Acosta Almeida, Guojing Zhao
1Department of Pathology, Institute of Cancer Genetics, Columbia University, New York, New York, USA.
Genes, Chromosomes & Cancer
|March 29, 2002
Summary
Prostate tumors may involve a deregulated APC/CTNNB1 pathway. Researchers found mutations in CTNNB1, APC, and hTRCP1 genes, suggesting CTNNB1 signaling is critical in prostate cancer development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Genetic alterations are key indicators of tumorigenesis pathways.
- Previous studies indicated CTNNB1 mutations in 5% of prostate tumors, suggesting APC/CTNNB1 pathway involvement.
Purpose of the Study:
- To investigate mutations in the APC/CTNNB1 pathway genes in prostate cancer.
- To determine the role of CTNNB1 signaling and its regulators in prostate tumorigenesis.
Main Methods:
- Screening of 22 prostate cancer samples (cell lines, xenografts, primary tumors) for mutations.
- Analysis of CTNNB1, APC, and hTRCP1 (BTRC) genes involved in CTNNB1 degradation.
Main Results:
- Identified seven genetic alterations: two in CTNNB1, three in APC, and two in hTRCP1.
- Observed mutual exclusivity of alterations in CTNNB1, APC, and hTRCP1, consistent with effects on CTNNB1 stability.
Conclusions:
- CTNNB1 signaling is crucial in a significant proportion of prostate cancer development.
- This study provides the first evidence for hTRCP1's role in human neoplasia.